Designing a First-in-Human Dose-Escalation Study of a Selective Covalent FGFR2 Inhibitor in FGFR2-Altered Advanced Solid Tumors: Starting-Dose Rationale, BOIN Escalation, and Phase 1 Protocol Synopsis
A selective kinase inhibitor is designed to avoid the toxicities of its less selective predecessors, and its first-in-human study must show that selectivity translates into a tolerable dose that still engages the target. This article develops a hypothetical first-in-human study of an oral, highly selective, irreversible FGFR2 inhibitor in adults with advanced solid tumors carrying FGFR2 fusions or other activating alterations, with intrahepatic cholangiocarcinoma as the population of principal interest. It derives a 20 mg once-daily starting dose from assumed ICH S9 toxicology benchmarks, specifies five dose levels from 20 to 70 mg in continuous 28-day cycles, and uses a Bayesian optimal interval (BOIN) design with a 25% target dose-limiting toxicity rate, 18 to 30 participants, and Safety Review Committee review before every escalation. The synopsis focuses monitoring on toxicities linked to FGFR inhibition: hyperphosphatemia, ocular, skin, mucosal, hepatic, and gastrointestinal effects. The article explains why the healthy-volunteer starting-dose guidance is not applied mechanically and why FDA's dose-optimization guidance shapes the design.Keywords: first-in-human; FGFR2; covalent inhibitor; cholangiocarcinoma; BOIN design; ICH S9; dose optimization; Phase 1 protocol
Authors
- Peivand Pirouzi
- Riddhi Rohan Moradiya
- Aditi Shivakumar Hipparagi
Institutions
- Northeastern University (US)
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-21
- DOI
- https://doi.org/10.5281/zenodo.24426547
- Primary Topic
- Statistical Methods in Clinical Trials
- Type
- article
- Field-Weighted Citation Impact
- 0.00